Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study

Giorgio, Mustacchi; Paolo, Pronzato; Alessia, D'Alonzo; Carmela, Mocerino; Emanuela, Romagnoli; Ornella, Garrone; Livio, Blasi; Michelino De Laurentiis,; Andrea, Michelotti; Alessandra, Bologna; Monica, Giordano; Anna, Turletti; Filippo, Montemurro; Sabino De Placido,; Natoli, Clara; Cristiana, Taverniti; Laura, Biganzoli; Icro, Meattini; Paolo, Marchetti; Marina Elena Cazzaniga,

doi:10.1200/JCO.2018.36.15_suppl.e13078

CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP) and greater overall survival (OS) in ABC pts treated with second-line or greater therapy. The improved safety and efficacy profile for Nab-P compared with solvent-based taxanes suggests that Nab-P may be particularly useful in older patients. A post-hoc analysis showed that weekly Nab-P (wNab-P) was safe and more efficacious in comparison to the q3w schedule and with solvent-based taxanes in older patients with ABC. Aim of the present analysis is to describe the use of Nab-P in the elderly (≥ 65 years) population registered in the GIM-13 AMBRA study.

Titolo:	Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study
Autori:	Giorgio Mustacchi Paolo Pronzato Alessia D'Alonzo Carmela Mocerino Emanuela Romagnoli Ornella Garrone Livio Blasi Michelino De Laurentiis Andrea Michelotti Alessandra Bologna Monica Giordano Anna Turletti Filippo Montemurro Sabino De Placido NATOLI, Clara Cristiana Taverniti Laura Biganzoli Icro Meattini Paolo Marchetti Marina Elena Cazzaniga mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2018
Rivista:	JOURNAL OF CLINICAL ONCOLOGY
Abstract:	Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP) and greater overall survival (OS) in ABC pts treated with second-line or greater therapy. The improved safety and efficacy profile for Nab-P compared with solvent-based taxanes suggests that Nab-P may be particularly useful in older patients. A post-hoc analysis showed that weekly Nab-P (wNab-P) was safe and more efficacious in comparison to the q3w schedule and with solvent-based taxanes in older patients with ABC. Aim of the present analysis is to describe the use of Nab-P in the elderly (≥ 65 years) population registered in the GIM-13 AMBRA study.
Handle:	http://hdl.handle.net/11564/696822
Appare nelle tipologie:	1.5 Abstract in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11564/696822

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.